Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLC

Video

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Terence T. Sio, MD, MS, radiation oncologist and assistant professor of radiation oncology at Mayo Clinic, discusses the standard-of-care dose of radiation therapy in locally advanced, non—small cell lung cancer (NSCLC).

In the modern era, the standard-of-care for patients with locally advanced NSCLC who require concurrent chemotherapy and radiation therapy is 60 gray (Gy), says Sio. This dosage is delivered Monday through Friday, at 2 Gy/day per fraction, for the duration of 6 weeks.

The NRG Oncology RTOG 0617 trial set out to determine whether a higher dose of radiation, 74 Gy, with concurrent chemotherapy would be more beneficial than the standard dose of 60 Gy, in patients with unresectable stage III NSCLC, says Sio. Investigators noted more adverse events in those who received the higher dose, with no improvement in overall survival. As such, 60 Gy continues to be the standard-of-care radiation dose in this patient population, concludes Sio.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.